Neurizon’s Managing Director and CEO, Dr Michael Thurn, described the FDA’s clearance as “a defining moment” for the company’s mission to accelerate access to innovative therapies for people living with ALS. …
FDA clears clinical hold on Neurizon's NUZ-001, paving way for HEALEY ALS trial
October 7, 2025 Australian Biotech
Latest Video
New Stories
-
New report highlights widening gap in access to modern medicines between Australia and NZ
October 8, 2025 - - Latest News -
RACGP warns of mounting pressure on GPs as costs and complexity rise
October 7, 2025 - - Other Health -
AusBiotech’s annual report highlights a defining year for Australia’s life sciences sector
October 7, 2025 - - Australian Biotech -
AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime
October 7, 2025 - - Latest News -
MTPConnect and Wholesale Investor unite to accelerate investment in life sciences sector
October 7, 2025 - - Australian Biotech -
Percheron Therapeutics reports positive final data from early-phase trial of HMBD-002
October 7, 2025 - - Australian Biotech -
FDA clears clinical hold on Neurizon's NUZ-001, paving way for HEALEY ALS trial
October 7, 2025 - - Australian Biotech